Proteasome Inhibitors

Proteasome Inhibitor

Multiple Myeloma

<section class="Section" data-sectioncode="34089-3"><a name="S11"></a><a name="section-9"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">Carfilzomib is a proteasome inhibitor. The chemical name for carfilzomib is (2S)-N-((S)-1-((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-ylcarbamoyl)-2-phenylethyl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)-4-methylpentanamide. Carfilzomib has the following structure:</p><p><img alt="Chemical Structure" src="kyprolis-02.jpg"/></p><p>Carfilzomib is a crystalline substance with a molecular weight of 719.9. The molecular formula is C<span class="Sub">40</span>H<span class="Sub">57</span>N<span class="Sub">5</span>O<span class="Sub">7</span>. Carfilzomib is practically insoluble in water and very slightly soluble in acidic conditions.</p><p>Kyprolis for injection, for intravenous use is a sterile, white to off-white lyophilized powder in a single-dose vial. Each 10 mg vial contains 10 mg of carfilzomib, 500 mg sulfobutylether beta-cyclodextrin, and 9.6 mg anhydrous citric acid and sodium hydroxide for pH adjustment (target pH 3.5). Each 30 mg vial contains 30 mg of carfilzomib, 1500 mg sulfobutylether beta-cyclodextrin, and 28.8 mg anhydrous citric acid and sodium hydroxide for pH adjustment (target pH 3.5). Each 60 mg vial contains 60 mg of carfilzomib, 3000 mg sulfobutylether beta-cyclodextrin, 57.7 mg citric acid, and sodium hydroxide for pH adjustment (target pH 3.5).</p></section>

KYPROLIS

carfilzomib

Kyprolis

carfilzomib 30 MG Injection

carfilzomib 30 MG Injection [Kyprolis]

carfilzomib 60 MG Injection

carfilzomib 60 MG Injection [Kyprolis]

carfilzomib 10 MG Injection

carfilzomib 10 MG Injection [Kyprolis]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event

Prescribing Information

Submit MSL Request 

Reimbursement Information

Billing & Coding Guide - Hospital Outpatient 

Billing & Coding Guide - Physician Office

Benefit Verification & PA Form 

Coverage Authorization Request 

Coverage Authorization Appeals 

Letter of Medical Necessity

Enroll in Patient Savings Program 

Amgen SupportPlus Enrollment Form 

Other HCP Resources 

About Kyprolis

Side Effects 

Receiving Kyprolis

Patient Stories 

FAQs: Relapsed or Refractory Multiple Myeloma 

Instructions For Use: Relapsed or Refractory Multiple Myeloma 

Kyprolis Patient Support Program

Patient Resources 

Patient Brochure 

Patient Lab Results Tracker 

Pharmacy List 